REGENERON PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2011

Regeneron Pharmaceuticals, Inc. (REGN) reported its 2011 annual results, showcasing significant progress and strategic advancements. The company achieved a major milestone with the U.S. FDA approval and launch of EYLEA® for wet age-related macular degeneration (wet AMD), a condition with a substantial market. This launch began generating product sales in the fourth quarter of 2011. Alongside EYLEA®, ARCALYST® continued its commercialization for rare auto-inflammatory conditions, though its future sales are not expected to be significant. The company also advanced its pipeline, with ZALTRAP® submitted for marketing approval in the U.S. and EU for metastatic colorectal cancer. Financially, Regeneron continued to invest heavily in research and development, leading to an increase in its net loss for 2011 compared to 2010, primarily driven by higher R&D and selling, general, and administrative expenses. However, the company bolstered its financial position by raising significant capital through a private placement of convertible senior notes, indicating a focus on funding its ongoing development programs and potential commercialization efforts. The strong collaboration with Sanofi and Bayer HealthCare remained a key revenue driver, providing substantial funding for research and development activities. Overall, the report highlights Regeneron's transition towards a commercial-stage biopharmaceutical company, marked by the successful launch of a key product and a robust pipeline. While R&D investments are impacting near-term profitability, the company's strategic partnerships and capital raise position it for future growth, contingent on the successful development and commercialization of its product candidates.